Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 11/20 | 0.78 |
| ▸ | MMP3 | P08254 | 7/20 | 0.78 |
| ▸ | MMP7 | P09237 | 7/20 | 0.77 |
| ▸ | ADAM17 | P78536 | 8/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP10 | P09238 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790775 | 0.98 | MMP12 (0.77) | MMP12MMP3MMP7ADAM17MMP2 | |
| SCHEMBL6788897 | 0.98 | MMP12 (0.77) | MMP12MMP3MMP7ADAM17MMP2 | |
| SCHEMBL6797719 | 0.97 | MMP12 (0.76) | MMP12MMP3MMP7ADAM17MMP2 | |
| SCHEMBL6795369 | 0.88 | MMP12 (0.77) | MMP12MMP3MMP7ADAM17MMP2 | |
| SCHEMBL6789643 | 0.88 | MMP12 (1.00) | MMP12MMP3MMP7ADAM17MMP2 | |
| SCHEMBL6790127 | 0.87 | MMP12 (0.62) | MMP12MMP3MMP7ADAM17 | |
| SCHEMBL6791947 | 0.87 | MMP12 (0.85) | MMP12MMP3MMP7ADAM17 | |
| SCHEMBL6793836 | 0.87 | MMP12 (1.00) | MMP12MMP3MMP7ADAM17MMP2 | |
| SCHEMBL6789656 | 0.87 | MMP12 (1.00) | MMP12MMP3MMP7ADAM17MMP2 | |
| SCHEMBL6786615 | 0.86 | MMP12 (0.90) | MMP12MMP3MMP7ADAM17MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6740649-B2 | ANTIINFLAMMATORY AGENTS; OSTEOPOROSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-25 | — | — | US | claimed |
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-24 | — | — | US | claimed |
| US-6740649-B2 | ANTIINFLAMMATORY AGENTS; OSTEOPOROSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-25 | — | — | US | disclosed |
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAMTS1, MMP1, ADAM17 | MMP12 24/4885MMP3 16/4885MMP7 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.